MRTX - Mirati Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.513B

Cash

783M

Avg Qtr Burn

-147M

Short % of Float

13.92%

Insider Ownership

6.89%

Institutional Own.

-

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Adagrasib (MRTX849) KRAS G12C Inhibitor Details Cancer, Lung cancer, Solid tumor/s, Colorectal cancer , Non-small cell lung carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sitravatinib (TAM inhibitor) plus nivolumab (OPDIVO®) Details Non-small cell lung carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (MRTX849) + cetuximab Details Solid tumor/s, Colorectal cancer , Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KRAZATI (Adagrasib) (MRTX849) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (MRTX849) + Pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MRTX0902 (Potent SOS1 inhibitor) +adagrasib Details Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MRTX1133 Details Solid tumor/s, Cancer, Colorectal cancer , Pancreatic cancer, Lung cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (MRTX849) KRAS G12C Inhibitor + VS-6766 in KRASG12C-mutant Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MRTX1719 (PRMT5 inhibitor) Details Solid tumor/s, Cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sitravatinib plus tislelizumab Details Platinum-resistant ovarian cancer	Phase 1b Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.